Amphastar Pharmaceuticals, Inc. Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation
Amphastar Pharmaceuticals, Inc. (AMPH) reported Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation of $421.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2019-03-15.
Discontinued › Notes › Compensation Related Costs
us-gaap:AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation · last filed 2019-03-15
- Amphastar Pharmaceuticals, Inc. adjustments to additional paid in capital, income tax deficiency from share-based compensation for fiscal 2016 was $421.00K.
- Amphastar Pharmaceuticals, Inc. adjustments to additional paid in capital, income tax deficiency from share-based compensation for fiscal 2014 was $1.11M.
| Period end | Adjustments to Additional Paid in Capital, Income Tax Deficiency from Share-based Compensation 12 month |
|---|---|
| 2016-12-31 | $421.00K 10-K · filed 2019-03-15 |
| 2014-12-31 | $1.11M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |